<DOC>
	<DOCNO>NCT00747799</DOCNO>
	<brief_summary>This study phase II clinical study . Recurrence radiotherapy patient failure radiotherapy recurrent metastatic nasopharyngeal carcinoma ( NPC ) treat cisplatin 5-fluorouracil Sorafenib first-line treatment . The objective response ( complete response ( CR ) + partial response ( PR ) ) , Disease Control Rate , safety profile , tolerability evaluate accord World Health Organization ( WHO ) criterion .</brief_summary>
	<brief_title>Study Combination Sorafenib With Cisplatin 5-fluorouracil First-line Treatment Recurrence After Radiotherapy Patients Who Failed With Radiotherapy Recurrent Metastatic Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . ECOG Performance Status 0 1 3 . Life expectancy least 12 week 4 . Pathologically confirm nasopharyngeal carcinoma 5 . Experience treatment failure radiotherapy recurrent metastatic NPC 6 . More 3 week must elapse since previous radiotherapy 7 . Biomarkers measure include pERK , EGFR original diagnostic paraffinembedded tumor sample ; VEGF predose postdose plasma sample . 8 . Subjects least one ( RECIST ) measurable lesion ( Tumor lesion situate previously irradiate area could consider measurable ) 9 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 100,000/Î¼l Total bilirubin &lt; 1.5 time upper limit normal ALT AST &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) , Alkaline phosphatase &lt; 4 x ULN , PTINR/PTT &lt; 1.5 x upper limit normal , Serum creatinine &lt; 1.5 x upper limit normal 10 . Signed date informed consent start specific protocol procedure 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . History HIV infection 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 5 . History organ allograft organ allograft may allow protocol specific . 6 . Patients evidence history bleeding diatheses 7 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . 8 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial two week completion trial . 9 . Patients unable swallow oral medication 10 . Prior use farnesyl transferase , Raf kinase , MEK inhibitors 11 . Investigational drug therapy outside trial within 4 week study entry 12 . Prior exposure study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent metastatic Nasopharyngeal Neoplasms</keyword>
</DOC>